Turna Ray

Somatic testing of patient with hematologic malignancy leads to discovery of critical chromosomal and germline findings that she didn't know about.

Precision Oncology News' 2022 survey showed doctors are increasingly offering molecular testing to earlier-stage patients, but institutions still need to do better to ensure patients have equitable access.

A patient of African-American descent with triple-negative breast cancer cannot get her genetic test results from a surgeon's office because of an outstanding bill.

The OSUCCC researchers plan to prospectively study how well patients with PD-L1/2 structural variants do on anti-PD-1 therapy and are seeking pharma partners for that effort.

After the VALID Act didn't pass, it's uncertain how the FDA will proceed, though some payors aren't waiting for the status quo to change and asking labs to submit additional validation data on cancer tests.

The FDA approved 21 precision oncology drugs and several companion tests, but the field continued to be plagued by intractable systemic challenges limiting access.

At SABCS, updated analysis from the EMERALD study showed that length of prior CDK4/6 inhibitor treatment impacts SERD response, particularly in patients with ESR1-mutated tumors.

At SABCS, experts in oncology and pathology discussed whether HER2-low tumors are a distinct subtype and how to reduce scoring variability and make tests more quantitative.

In this preliminary analysis, researchers also explored how HER2 expression changed with Enhertu treatment and discordance between labs in gauging HER2 low expression.

Before drawing definitive conclusions, however, researchers should look at ancestry instead of self-reported race, consider social determinants of health, and improve diversity in trials, experts said.